Enhancing Radiotherapy Outcomes in Rectal Cancer: A Systematic Review of Targeting Hypoxia-induced Radioresistance

Overview

Journal Clin Transl Radiat Oncol

Specialty Oncology

Date 2023 Nov 14

PMID 37961749

Authors

Matthew Fok

Rhianna Hill

Hayley Fowler

Rachael Clifford

Aaron Kler

Jayanma Uzzi-Daniel

Sonia Rocha

Gabrielle Grundy

Jason Parsons

Dale Vimalachandran

Affiliations

Soon will be listed here.

Abstract

Introduction: Neoadjuvant radiotherapy is successfully used in rectal cancer to improve overall survival. However, treatment response is both unpredictable and variable. There is strong evidence to show that the phenomenon of tumour hypoxia is associated with radioresistance, however the mechanism(s) behind this are poorly understood. Consequently, there have only been a small number of studies evaluating methods targeting hypoxia-induced radioresistance. The purpose of this systematic review is to evaluate the potential effectiveness of targeting hypoxia-induced radioresistance in rectal cancer and provide recommendations for future research in this area.

Methods: A comprehensive literature search was performed following the PRISMA guidelines. This study was registered on the Prospero database (CRD42023441983).

Results: Eight articles met the inclusion criteria. All studies identified were or studies, there were no clinical trials. Of the 8 studies identified, 5 assessed the efficacy of drugs which directly or indirectly targeted hypoxia and three that identified potential targets. There was conflicting evidence for the use of metformin to overcome hypoxia induced radioresistance. Vorinostat, atovaquone, and evofosfamide showed promising preclinical evidence that they can overcome hypoxia-induced radioresistance.

Discussion: The importance of investigating hypoxia-induced radioresistance in rectal cancer is crucial. However, to date, only a small number of preclinical studies exist evaluating this phenomenon. This systematic review highlights the importance of further research to fully understand the mechanism behind this radioresistance. There are promising targets identified in this systematic review however, substantially more pre-clinical and clinical research as a priority for future research is needed.

References

Gupta N, Srivastava S . Atovaquone: An Antiprotozoal Drug Suppresses Primary and Resistant Breast Tumor Growth by Inhibiting HER2/β-Catenin Signaling. Mol Cancer Ther. 2019; 18(10):1708-1720. PMC: 6905100. DOI: 10.1158/1535-7163.MCT-18-1286. View

Overgaard J, Hansen H, Overgaard M, Bastholt L, BERTHELSEN A, Specht L . A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol. 1998; 46(2):135-46. DOI: 10.1016/s0167-8140(97)00220-x. View

Macleod M, OCollins T, Howells D, Donnan G . Pooling of animal experimental data reveals influence of study design and publication bias. Stroke. 2004; 35(5):1203-8. DOI: 10.1161/01.STR.0000125719.25853.20. View

Haynes J, McKee T, Haller A, Wang Y, Leung C, Gendoo D . Administration of Hypoxia-Activated Prodrug Evofosfamide after Conventional Adjuvant Therapy Enhances Therapeutic Outcome and Targets Cancer-Initiating Cells in Preclinical Models of Colorectal Cancer. Clin Cancer Res. 2018; 24(9):2116-2127. DOI: 10.1158/1078-0432.CCR-17-1715. View

Melia E, Parsons J . DNA damage and repair dependencies of ionising radiation modalities. Biosci Rep. 2023; 43(10). PMC: 10548165. DOI: 10.1042/BSR20222586. View

Hansen T, Qvortrup C, Pfeiffer P . Angiogenesis Inhibitors for Colorectal Cancer. A Review of the Clinical Data. Cancers (Basel). 2021; 13(5). PMC: 7957514. DOI: 10.3390/cancers13051031. View

Ziello J, Jovin I, Huang Y . Hypoxia-Inducible Factor (HIF)-1 regulatory pathway and its potential for therapeutic intervention in malignancy and ischemia. Yale J Biol Med. 2007; 80(2):51-60. PMC: 2140184. View

Li Y, Zhao L, Li X . The Hypoxia-Activated Prodrug TH-302: Exploiting Hypoxia in Cancer Therapy. Front Pharmacol. 2021; 12:636892. PMC: 8091515. DOI: 10.3389/fphar.2021.636892. View

Wilson W, Hay M . Targeting hypoxia in cancer therapy. Nat Rev Cancer. 2011; 11(6):393-410. DOI: 10.1038/nrc3064. View

10.

Semenza G . Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003; 3(10):721-32. DOI: 10.1038/nrc1187. View

11.

Vaupel P, Mayer A . Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 2007; 26(2):225-39. DOI: 10.1007/s10555-007-9055-1. View

12.

Falk M, Lukasova E, Gabrielova B, Ondrej V, Kozubek S . Chromatin dynamics during DSB repair. Biochim Biophys Acta. 2007; 1773(10):1534-45. DOI: 10.1016/j.bbamcr.2007.07.002. View

13.

Melvin A, Rocha S . Chromatin as an oxygen sensor and active player in the hypoxia response. Cell Signal. 2011; 24(1):35-43. PMC: 3476533. DOI: 10.1016/j.cellsig.2011.08.019. View

14.

Xu H, Wu D, Gu J, Ge J, Wu J, Han R . The pro-survival role of autophagy depends on Bcl-2 under nutrition stress conditions. PLoS One. 2013; 8(5):e63232. PMC: 3643928. DOI: 10.1371/journal.pone.0063232. View

15.

Fok M, Toh S, Easow J, Fowler H, Clifford R, Parsons J . Proton beam therapy in rectal cancer: A systematic review and meta-analysis. Surg Oncol. 2021; 38:101638. DOI: 10.1016/j.suronc.2021.101638. View

16.

Hill R, Fok M, Grundy G, Parsons J, Rocha S . The role of autophagy in hypoxia-induced radioresistance. Radiother Oncol. 2023; 189:109951. PMC: 11046710. DOI: 10.1016/j.radonc.2023.109951. View

17.

Batie M, Frost J, Frost M, Wilson J, Schofield P, Rocha S . Hypoxia induces rapid changes to histone methylation and reprograms chromatin. Science. 2019; 363(6432):1222-1226. DOI: 10.1126/science.aau5870. View

18.

Bonnet M, Hong C, Wong W, Liew L, Shome A, Wang J . Next-Generation Hypoxic Cell Radiosensitizers: Nitroimidazole Alkylsulfonamides. J Med Chem. 2017; 61(3):1241-1254. DOI: 10.1021/acs.jmedchem.7b01678. View

19.

Hill R, Rocha S, Parsons J . Overcoming the Impact of Hypoxia in Driving Radiotherapy Resistance in Head and Neck Squamous Cell Carcinoma. Cancers (Basel). 2022; 14(17). PMC: 9454974. DOI: 10.3390/cancers14174130. View

20.

Evans S, Koch C . Prognostic significance of tumor oxygenation in humans. Cancer Lett. 2003; 195(1):1-16. DOI: 10.1016/s0304-3835(03)00012-0. View